Journal article

Publication year: 2021

Journal: Biochimica et Biophysica Acta (BBA) - General Subjects

Volume number: 1865

Issue number: 8

ISSN: 0304-4165

eISSN: 1872-8006

Open access status: Hybrid

DOI Link: https://doi.org/10.1016/j.bbagen.2021.129917

Publisher: Elsevier

Abstract: 
Background: Neurotensin receptor activation augments the biosctivity of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). JMV-449, a C-terminal neurotensin-like fragment with a reduced peptide bond, represents a neurotensin receptor agonist.Methods: The present study assessed the actions of JMV-449 on pancreatic beta-cells alone, and in combination with GIP and GLP-1. Further studies examined the impact of JMV-449 and incretin mimetics on glucose homeostasis and appetite control in mice.Results: JMV-449 was resistant to plasma enzyme degradation and induced noticeable dose-dependent insulin-releasing actions in BRIN-BD11 beta-cells. In combination with either GIP or GLP-1, JMV-449 augmented (P < 0.05) the insulinotropic actions of both hormones, as well as enhancing (P < 0.001) insulin secretory activity of both incretin peptides. JMV-449 also increased beta-cell proliferation and induced significant benefits on beta-cell survival in response to cytokine-induced apoptosis. JMV-449 (25 nmol/kg) inhibited (P < 0.05-P < 0.001) food intake in overnight fasted lean mice, and enhanced (P < 0.01) the appetite supressing effects of an enzymatically stable GLP-1 mimetic. When injected co-jointly with glucose, JMV-449 evoked glucose lowering actions, but more interestingly significantly augmented (P < 0.05) the glucose lowering effects of established long-acting GIP and GLP-1 receptor mimetics. In terms of glucose-induced insulin secretion, only GIP receptor signalling was associated with increases in insulin concentrations, and this was not enhanced by JMV-449.Conclusion: JMV-449 is a neurotensin receptor agonist that positively augments key aspects of the biological action profile of GIP and GLP-1.General significance: These observations emphasise the, yet untapped, therapeutic potential of combined neurotensin and incretin receptor signalling for diabetes.

Harvard Citation style: Craig, S., Gault, V., Shiels, C., Hamscher, G. and Irwin, N. (2021) Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control, Biochimica et Biophysica Acta (BBA) - General Subjects, 1865(8), Article 129917. https://doi.org/10.1016/j.bbagen.2021.129917

APA Citation style: Craig, S., Gault, V., Shiels, C., Hamscher, G., & Irwin, N. (2021). Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control. Biochimica et Biophysica Acta (BBA) - General Subjects. 1865(8), Article 129917. https://doi.org/10.1016/j.bbagen.2021.129917